On June 25, the high-profile 2023 top 100 series list of China's pharmaceutical industry was officially released at the 2024 Mises Conference on the intranet. The list was subdivided into five series, including "Top100 list of Chinese chemical pharmaceutical enterprises" and "Top100 list of Chinese traditional medicine enterprises".

Chengdu Baiyu Pharmaceutical Co., Ltd. won the top 100 list of Chinese traditional medicine enterprises in 2023 by virtue of its solid R & D and production strength and professional academic promotion ability. It has been recognized by the market for six consecutive years. In the future, Baiyu pharmaceutical will work together with colleagues in the industry to meet the new pattern of health care and create a new future for Chinese medicine!

It is reported that the "list of China's top 100 pharmaceutical industry series" is sponsored by the leading platform of China's pharmaceutical health information - minenet. It aims to set a benchmark for domestic pharmaceutical industry enterprises to improve their comprehensive strength and expand brand effectiveness, display the outstanding demeanor of pharmaceutical brand industry, and guide the steady, rapid and sustainable development of the pharmaceutical health industry. This selection focuses on the innovation driving force and professional promotion force of pharmaceutical industry enterprises. The innovation driving force is mainly evaluated from the r&d comprehensive index of enterprise R & D investment. The professional promotion force is rigidly defined according to the terminal quantitative data determined by the final selection needs of clinicians and patients. Finally, the quantitative analysis is carried out in combination with the terminal data of the three major terminals and six major markets exclusive to the intranet.

Founded in 2005 and headquartered in Chengdu, Sichuan Province, Chengdu Baiyu Pharmaceutical Co., Ltd. (hereinafter referred to as Baiyu pharmaceutical) is a pharmaceutical enterprise that focuses on the research and development of innovative drugs and integrates research, production and marketing. With the corporate mission of "serving the world for a hundred years and enjoying well-being", the goal of "meeting the unmet health needs of mankind" and the core drive of "scientific and technological innovation", Baiyu pharmaceutical focuses on the central nervous system, tumors, autoimmune diseases and anti-aging. Adhering to the corporate spirit of "never admit defeat in adversity and never lose in perseverance", Baiyu pharmaceutical constantly challenges the treatment problems of human diseases, and strives to develop safer, higher quality, more affordable and effective innovative drugs for the world!

Baiyu pharmaceutical adheres to the innovative development strategy, extensively expands domestic and foreign R & D cooperation, and vigorously introduces and cultivates international, professional and high-quality scientific research teams. Baiyu pharmaceutical is a national enterprise technology center, Sichuan natural terpene extraction and Separation Technology Engineering Research Center, Chengdu Ginkgo biloba pharmaceutical preparation engineering technology research center, with Academician (expert) workstation and post doctoral research workstation. Baiyu pharmaceutical has the pharmaceutical technology with independent intellectual property rights, an advanced production base with international quality control standards and a widely covered global sales network, providing excellent products and services for patients and the pharmaceutical industry worldwide!

Jingelai developed by Baiyu pharmaceutical ® Ginkgolide injection is a Ginkgo biloba preparation containing high-purity ginkgolide ABC and bilobalide. It can antagonize platelet activating factor and protect neurovascular unit, filling the deficiency of antiplatelet therapy. It is a therapeutic drug with high clinical application value. Its ingredients are clear, curative effect is significant, and has clinical value. It is a class B drug of national medical insurance.